GHRH receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
==== Film and television ==== In season 7 episode 12 of the series House, M.D. is about a patient who has a temporary paralysis and creatine kinase. She has a "perfect memory" due to her hyperthymesia. It later concludes her hyperthymesia is the way her OCD presents and that taking SSRI to treat her OCD will dial down her hyperthymesia. In the 2014 film The Dark Place, the protagonist of the story, Keegan Dark, has hyperthymesia. Keegan uses it to solve the mystery at the heart of the story. His hyperthymesia memories are visually depicted in the movie as "screens" appearing to Keegan, often in an overwhelming and distressing manner. In season 2 episode 2 of the TV show The Blacklist a character involved in criminal banking enterprises identified herself as having hyperthymesia as a skillful trait to avoid leaving a paper trail for illegal activities. She provided the FBI agents in the episode with real examples by recitation of events of dates selected at random. Her skills seemed to be date oriented rather than triggered by "personal experience." Unforgettable (American TV series) The 2015 South Korean TV series Remember: War of the Son portrays a hyperthymestic lawyer who sought to prove the innocence of his father, who had been convicted and sentenced to death for the brutal rape-murder of a neighbour. The 2020 South Korean TV series Find Me in Your Memory portrays the love story between a hyperthymestic news anchorman and an actress with amnesia, connected by a past traumatic event.
1993/1150) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) (Partial Revocation) Order 1993 (S.I. 1993/1151) Finance Act 1991 (Commencement and Transitional Provisions) Order 1993 (S.I. 1993/1152) Water Byelaws (Milngavie Waterworks, Loch Katrine, Loch Arklet, Glen Finglas) Extension Order 1993 (S.I. 1993/1153) Control of Pollution (Exemption of Certain Discharges from Control) (Scotland) Variation Order 1993 (S.I. 1993/1154) Control of Pollution (Registers) (Scotland) Regulations 1993 (S.I. 1993/1155) Control of Pollution (Discharges by Islands Councils) (Scotland) Regulations 1993 (S.I. 1993/1156) Robert Gordon University (Scotland) Order of Council 1993 (S.I. 1993/1157) Pneumoconiosis etc. (Workers' Compensation) (Payment of Claims) (Amendment) Regulations 1993 (S.I. 1993/1158) Social Security Revaluation of Earnings Factors Order 1993 (S.I. 1993/1159) Emulsifiers and Stabilisers in Food (Amendment) Regulations 1993 (S.I. 1993/1161) National Rivers Authority (Anglian Region) (Reconstitution of the Skegness District Internal Drainage Board) Order 1993 (S.I. 1993/1174) Reconstitution of the Denge and Southbrooks Internal Drainage Board Order 1993 (S.I. 1993/1175) Civil Aviation (Navigation Services Charges) (Third Amendment) Regulations 1993 (S.I. 1993/1176) Undersized Lobsters Order 1993 (S.I. 1993/1178) PARLIAMENT S.I. 1993/1181) Magistrates' Courts (Miscellaneous Amendments) Rules 1993 (S.I. 1993/1183) British Wool (Guaranteed Prices) (Revocation) Order 1993 (S.I. 1993/1184) Friendly Societies Act 1992 (Commencement No.
== Industrial production == Potassium alum historically was mainly extracted from alunite. Potassium alum is now produced industrially by adding potassium sulfate to a concentrated solution of aluminium sulfate. The aluminium sulfate is usually obtained by treating minerals like alum schist, bauxite and cryolite with sulfuric acid. If much iron should be present in the sulfate then it is preferable to use potassium chloride in place of potassium sulfate.
Ribosomes are a large and complex molecular machine that catalyzes the synthesis of proteins, referred to as translation. The ribosome selects aminoacylated transfer RNAs (tRNAs) based on the sequence of a protein-encoding messenger RNA (mRNA) and covalently links the amino acids into a polypeptide chain. Ribosomes from all organisms share a highly conserved catalytic center. However, the ribosomes of eukaryotes (animals, plants, fungi, and large number unicellular organisms all with a nucleus) are much larger than prokaryotic (bacterial and archaeal) ribosomes and subject to more complex regulation and biogenesis pathways. Eukaryotic ribosomes are also known as 80S ribosomes, referring to their sedimentation coefficients in Svedberg units, because they sediment faster than the prokaryotic (70S) ribosomes. Eukaryotic ribosomes have two unequal subunits, designated small subunit (40S) and large subunit (60S) according to their sedimentation coefficients. Both subunits contain dozens of ribosomal proteins arranged on a scaffold composed of ribosomal RNA (rRNA). The small subunit monitors the complementarity between tRNA anticodon and mRNA, while the large subunit catalyzes peptide bond formation.
Southern: The southern section runs from the New River and consists of the prolongation of the Blue Ridge Mountains, which is divided into the Western Blue Ridge (or Unaka) Front and the Eastern Blue Ridge Front, the Ridge-and-Valley Appalachians, and the Cumberland Plateau. This same plateau is known as the Cumberland Plateau in southern West Virginia, eastern Kentucky, far Southwest Virginia, eastern Tennessee, and northern Alabama.
Sources: en.wikipedia.org
In 1877, Schumacher adopted the Quaker symbol, the first registered trademark for a breakfast cereal. The acceptance of "horse food" for human consumption encouraged other entrepreneurs to enter the industry. Henry Parsons Crowell started operations in 1882, and John Robert Stuart in 1885. Crowell cut costs by consolidating every step of the processing—grading, cleaning, hulling, cutting, rolling, packaging, and shipping—in one factory operating at Ravenna, Ohio. Stuart operated mills in Chicago and Cedar Rapids, Iowa. Stuart and Crowell combined in 1885 and initiated a price war. After a fire at his mill in Akron, Schumacher joined Stuart and Crowell to form the Consolidated Oatmeal Company. The American Cereal Company (Quaker Oats, but see below) created a cereal made from oats in 1877, manufacturing the product in Akron, Ohio. Separately, in 1888, a trust or holding company combined the nation's seven largest mills into the American Cereal Company using the Quaker Oats brand name. By 1900, technology, entrepreneurship, and the "Man in Quaker Garb"—a symbol of plain honesty and reliability—gave Quaker Oats a national market and annual sales of $10 million (equivalent to $390 million today). Early in the 20th century, the Quaker Oats Company (formed in 1901 to replace the American Cereal Company) ventured into the world market. Schumacher, the innovator; Stuart, the manager and financial leader; and Crowell, the creative merchandiser, advertiser, and promoter, doubled sales every decade. Alexander P.
Upon adding phenol to deuterated water (water containing D2O in addition to the usual H2O), a hydrogen-deuterium exchange is observed to affect phenol's hydroxyl group (resulting in C6H5OD), indicating that phenol readily undergoes hydrogen-exchange reactions with water. Mainly the hydroxyl group is affected—without a catalyst, the other five hydrogen atoms are much slower to undergo exchange—reflecting the difference in chemical environments between the hydroxyl hydrogen and the aryl hydrogens.
Horse racing is by far the most popular spectator sport in Hong Kong and generates the largest horse race gambling turnover in the world. British tradition left its mark as one of the most important entertainment and gambling institutions in Hong Kong. Established as the Royal Hong Kong Jockey Club in 1884, the non-profit organization conducts nearly 700 races every season at the two race tracks in Happy Valley and Sha Tin. The sport annually draws in over 11% of Hong Kong's tax revenue. Off-track betting is available from overseas bookmakers. In 2009, betting on horse races generated an average US$12.7 million in gambling turnover per race, 6 times larger than its closest rival France at US$2 million, while the United States only generated $250,000. Some consider betting on horse races an investment.
=== Gene therapy === Gene therapy for hemoglobinopathies was first trialled in 2014 on a single patient with sickle cell disease (a fault in the beta globin gene), and followed by clinical trials in which a number of patients with either sickle cell or beta thalassemia were successfully treated. Gene therapies work by first harvesting the patient's HSCs, then using CRISPR gene editing to modify their DNA in the laboratory. In parallel with this, the person with thalassemia disease undergoes a myeloablation procedure (a form of chemotherapy) to destroy the remaining HSCs in their bone marrow. The laboratory treated cells are then infused back into the patient where they colonise the bone marrow and eventually commence production of healthy blood cells. There are fewer risks from this procedure than from HSCT, since the transplanted cells are autologous having originated from the patient herself/himself. There are two approved forms of gene therapy for beta thalassemia. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia which adds a healthy beta-globin gene to the HSCs. It was approved for medical use in the United States in August 2022. The procedure involves collecting hematopoietic stem cells (HSCs) from the affected person's blood. In the laboratory, these HSCs then have a new gene for T87Q-globin (a modified beta-globin) introduced to them using a lentiviral vector.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.